Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.

Landre T, Uzzan B, Nicolas P, Aparicio T, Zelek L, Mary F, Taleb C, Des Guetz G.

Int J Colorectal Dis. 2015 Oct;30(10):1305-10. doi: 10.1007/s00384-015-2296-5. Epub 2015 Jun 23. Review.

PMID:
26099322
2.
3.

Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).

Des Guetz G, Landre T, Westeel V, Milleron B, Vaylet F, Urban T, Barlesi F, Souquet PJ, Debieuvre D, Braun D, Fraboulet G, Monnet I, Uzzan B, Molinier O, Morin F, Moro-Sibilot D, Morère JF.

J Geriatr Oncol. 2015 May;6(3):233-40. doi: 10.1016/j.jgo.2015.02.002. Epub 2015 Feb 16.

PMID:
25698450
4.

Systematic review and bivariate/HSROC random-effect meta-analysis of immunochemical and guaiac-based fecal occult blood tests for colorectal cancer screening.

Launois R, Le Moine JG, Uzzan B, Fiestas Navarrete LI, Benamouzig R.

Eur J Gastroenterol Hepatol. 2014 Sep;26(9):978-89. doi: 10.1097/MEG.0000000000000160. Review.

PMID:
25072382
5.

Impact of physical activity on cancer-specific and overall survival of patients with colorectal cancer.

Des Guetz G, Uzzan B, Bouillet T, Nicolas P, Chouahnia K, Zelek L, Morere JF.

Gastroenterol Res Pract. 2013;2013:340851. doi: 10.1155/2013/340851. Epub 2013 Oct 3. Review.

6.

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.

Des Guetz G, Uzzan B, Nicolas P, Valeyre D, Sebbane G, Morere JF.

Crit Rev Oncol Hematol. 2012 Dec;84(3):340-9. doi: 10.1016/j.critrevonc.2012.03.007. Epub 2012 Apr 23.

PMID:
22534083
7.

[Sarcoidosis: the involvement of anterior pituitary hormones is poorly recognized].

Bihan H, Guillot H, Fysekidis M, Cohen R, Gille T, Nunes H, Uzzan B, Valeyre D.

Presse Med. 2012 Oct;41(10):e524-9. doi: 10.1016/j.lpm.2012.01.038. Epub 2012 Apr 16. French.

PMID:
22513205
8.

Identification and chemoprevention in subjects at moderate risk of colorectal cancer.

Benamouzig R, Uzzan B.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):631-40. doi: 10.1016/j.bpg.2011.09.001. Review.

PMID:
22122777
9.

Cardiovascular toxicity of anti-angiogenic drugs.

des Guetz G, Uzzan B, Chouahnia K, Morère JF.

Target Oncol. 2011 Dec;6(4):197-202. doi: 10.1007/s11523-011-0204-7. Epub 2011 Nov 25. Review.

PMID:
22116787
10.

Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial.

Benamouzig R, Uzzan B, Deyra J, Martin A, Girard B, Little J, Chaussade S; Association pour la Prévention par l'Aspirine du Cancer Colorectal Study Group (APACC).

Gut. 2012 Feb;61(2):255-61. doi: 10.1136/gutjnl-2011-300113. Epub 2011 Sep 2. Erratum in: Gut. 2012 Mar;61(3):472.

PMID:
21890814
12.

Metformin and digestive disorders.

Bouchoucha M, Uzzan B, Cohen R.

Diabetes Metab. 2011 Apr;37(2):90-6. doi: 10.1016/j.diabet.2010.11.002. Epub 2011 Jan 13. Review.

PMID:
21236717
13.

Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX.

Des Guetz G, Lecaille C, Mariani P, Bennamoun M, Uzzan B, Nicolas P, Boisseau A, Sastre X, Cucherousset J, Lagorce C, Schischmanoff PO, Morere JF.

Anticancer Res. 2010 Oct;30(10):4297-301.

PMID:
21036755
14.

Aspirin to prevent colorectal cancer: time to act?

Benamouzig R, Uzzan B.

Lancet. 2010 Nov 20;376(9754):1713-4. doi: 10.1016/S0140-6736(10)61509-7. Epub 2010 Oct 21. No abstract available.

PMID:
20970845
15.

An anticancer strategic dilemma: to kill or to contain. The choice of the pharmaceutical industry in 2009.

Perret GY, Uzzan B.

Fundam Clin Pharmacol. 2011 Jun;25(3):283-95. doi: 10.1111/j.1472-8206.2010.00849.x. Review.

PMID:
20608993
16.

Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.

Benamouzig R, Uzzan B, Martin A, Deyra J, Little J, Girard B, Chaussade S; APACC Study Group.

Gut. 2010 May;59(5):622-9. doi: 10.1136/gut.2008.175406.

PMID:
20427397
17.

Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis.

Des Guetz G, Nicolas P, Perret GY, Morere JF, Uzzan B.

Eur J Cancer. 2010 Apr;46(6):1049-55. doi: 10.1016/j.ejca.2010.01.020.

PMID:
20138505
18.

Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer.

Des Guetz G, Uzzan B, Morere JF, Perret G, Nicolas P.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007046. doi: 10.1002/14651858.CD007046.pub2. Review.

PMID:
20091614
19.

Efficacy of four insect repellents against mosquito bites: a double-blind randomized placebo-controlled field study in Senegal.

Uzzan B, Konate L, Diop A, Nicolas P, Dia I, Dieng Y, Izri A.

Fundam Clin Pharmacol. 2009 Oct;23(5):589-94. doi: 10.1111/j.1472-8206.2009.00731.x.

PMID:
19744033
20.

Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis.

Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, Morere JF.

Anticancer Res. 2009 May;29(5):1615-20. Review.

21.

Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B.

Eur J Cancer. 2009 Jul;45(10):1890-6. doi: 10.1016/j.ejca.2009.04.018. Epub 2009 May 6. Review.

PMID:
19427194
22.

Microsatellite instability: a predictive marker in metastatic colorectal cancer?

Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Morere JF.

Target Oncol. 2009 Jan;4(1):57-62. doi: 10.1007/s11523-008-0103-8. Epub 2009 Jan 17.

PMID:
19343302
23.

Factitious increases in serum testosterone concentrations related to phenylbutazone therapy.

Uzzan B, Dumont-Fischer D, Lahlou N, Bihan H, Boissier MC, Alvarez JC, Perret GY, Cohen R.

Fundam Clin Pharmacol. 2008 Apr;22(2):159-60. doi: 10.1111/j.1472-8206.2007.00564.x.

PMID:
18353110
24.

Expression of ghrelin in fundus is increased after gastric banding in morbidly obese patients.

Uzzan B, Catheline JM, Lagorce C, Airinei G, Bon C, Cohen R, Perret GY, Aparicio T, Benamouzig R.

Obes Surg. 2007 Sep;17(9):1159-64.

PMID:
18074488
25.

[Sunitinib and hypothyroidism].

Cohen R, Bihan H, Uzzan B, des Guetz G, Krivitzky A.

Ann Endocrinol (Paris). 2007 Oct;68(5):332-6. Epub 2007 Aug 20. Review. French.

PMID:
17707761
26.

Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer.

des Guetz G, Mariani P, Cucherousset J, Benamoun M, Lagorce C, Sastre X, Le Toumelin P, Uzzan B, Perret GY, Morere JF, Breau JL, Fagard R, Schischmanoff PO.

Anticancer Res. 2007 Jul-Aug;27(4C):2715-9. Erratum in: Anticancer Res. 2007 Sep-Oct;27(5b):3667.

27.

Is sentinel lymph node mapping in colorectal cancer a future prognostic factor? A meta-analysis.

Des Guetz G, Uzzan B, Nicolas P, Cucherat M, de Mestier P, Morere JF, Breau JL, Perret G.

World J Surg. 2007 Jun;31(6):1304-12.

PMID:
17460811
28.

Effects of statins on bone mineral density: a meta-analysis of clinical studies.

Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY.

Bone. 2007 Jun;40(6):1581-7. Epub 2007 Mar 1.

PMID:
17409043
29.

Serum procalcitonin in uncomplicated falciparum malaria: a preliminary study.

Uzzan B, Izri A, Durand R, Deniau M, Bouchaud O, Perret GY.

Travel Med Infect Dis. 2006 Mar;4(2):77-80. Epub 2005 Jul 1.

PMID:
16887728
30.

Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature.

Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, Perret GY.

Br J Cancer. 2006 Jun 19;94(12):1823-32.

31.

Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis.

Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY.

Crit Care Med. 2006 Jul;34(7):1996-2003. Review.

PMID:
16715031
32.

Ghrelin levels and sleeve gastrectomy in super-super-obesity.

Cohen R, Uzzan B, Bihan H, Khochtali I, Reach G, Catheline JM.

Obes Surg. 2005 Nov-Dec;15(10):1501-2. No abstract available.

PMID:
16354535
33.

Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer.

Benamouzig R, Uzzan B, Little J, Chaussade S.

Curr Top Med Chem. 2005;5(5):493-503. Review.

PMID:
15974944
34.
35.

Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.

Tod M, Lortholary O, Seytre D, Semaoun R, Uzzan B, Guillevin L, Casassus P, Petitjean O.

Antimicrob Agents Chemother. 1998 Apr;42(4):849-56.

36.

Predictive value of serum sex hormone binding globulin for the occurrence of hepatocellular carcinoma in male patients with cirrhosis.

Ganne-Carrié N, Chastang C, Uzzan B, Pateron D, Trinchet JC, Perret G, Beaugrand M.

J Hepatol. 1997 Jan;26(1):96-102.

PMID:
9148029
37.

Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis.

Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY.

J Clin Endocrinol Metab. 1996 Dec;81(12):4278-89.

PMID:
8954028
38.

Effects of aerosolized pentamidine on glucose homeostasis and insulin secretion in HIV-positive patients: a controlled study.

Uzzan B, Bentata M, Campos J, Mosnier A, Krivitzky A, Perret GY, Modigliani E.

AIDS. 1995 Aug;9(8):901-7.

PMID:
7576325
39.

Transient hypocalcemia after thyroidectomy.

Bourrel C, Uzzan B, Tison P, Despreaux G, Frachet B, Modigliani E, Perret GY.

Ann Otol Rhinol Laryngol. 1993 Jul;102(7):496-501.

PMID:
8333670
40.

Troleandomycin hepatotoxicity: a case report of overt jaundice and a placebo-controlled trial.

Uzzan B, Vassy R, Nicolas P, Chapman A, Perret G.

Therapie. 1993 Jan-Feb;48(1):61-2. No abstract available.

PMID:
8356550
41.

In vivo effects of amiodarone on cardiac beta-adrenoceptor density and heart rate require thyroid hormones.

Yin YL, Perret GY, Nicolas P, Vassy R, Uzzan B, Tod M.

J Cardiovasc Pharmacol. 1992 Apr;19(4):541-5.

PMID:
1380596
42.

Amiodarone decreases cardiac beta-adrenoceptors through an antagonistic effect on 3,5,3' triiodothyronine.

Perret G, Yin YL, Nicolas P, Pussard E, Vassy R, Uzzan B, Berdeaux A.

J Cardiovasc Pharmacol. 1992 Apr;19(4):473-8.

PMID:
1380587
43.

Effect of nifedipine and nitrendipine on insulin release in non-diabetic obese patients: a double-blind, placebo-controlled study.

Valensi P, Uzzan B, Vassy R, Attali JR, Perret G.

Methods Find Exp Clin Pharmacol. 1991 Oct;13(8):557-63.

PMID:
1956211
44.

The effects of plasmapheresis on thyroid hormone and plasma drug concentrations in amiodarone-induced thyrotoxicosis.

Uzzan B, Pussard E, Leon A, Bekhechi D, Krivitzky A, Modigliani E, Perret G, Vassy R, Berdeaux A, Giudicelli JF.

Br J Clin Pharmacol. 1991 Mar;31(3):371-2. No abstract available.

46.
47.

Effects of nifedipine and nitrendipine on insulin secretion in obese patients.

Valensi P, Uzzan B, Attali JR, Perret G.

J Cardiovasc Pharmacol. 1991;18 Suppl 1:S91-3.

PMID:
1723467
48.

Amiodarone: influence of the route of administration on thyroid status and cardiac beta-adrenoceptors in the rat.

Yin YL, Nicolas P, Vassy R, Uzzan B, Pussard E, Berdeaux A, Perret G.

Fundam Clin Pharmacol. 1991;5(6):491-5.

PMID:
1659555
49.

Effect of nifedipine on thyrotropin, prolactin, and thyroid hormone release in man: a placebo-controlled study.

Valensi P, Perret G, Vassy R, Uzzan B, Nicolas P, Attali JR.

Fundam Clin Pharmacol. 1989;3(1):59-66.

PMID:
2497058
50.

Use of a pharmacokinetic model to characterize the thyrotropin (TSH) and prolactin (PRL) response to thyrotropin-releasing hormone (THR) in man.

Perret G, Valensi P, Hugues JN, Vassy R, Uzzan B.

Methods Find Exp Clin Pharmacol. 1988 Jun;10(6):387-91.

PMID:
3137402

Supplemental Content

Support Center